First-of-its-kind study on 266 men found 20% have higher levels of the hormone in the vessels surrounding the prostate.
Aadi says its solid tumor drug is unlikely to succeed, winding down the trial and axing staffers
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS